Replies to post #4706 on Antares Pharma, Inc. (ATRS)

[H2R]

New SoS article after the Jefferies Healthcare Conference

Larry continues to be optimistic about the launch and market share for Xyosted and the EpiPen.

https://smithonstocks.com/antares-pharma-highlights-from-presentation-at-jefferies-healthcare-conference-atrs-buy-4-79/

Interesting info on his blog.

One basic takeaway:

Sales guidance for 2019 has been raised twice over the course of the year. Latest guidance for 2019 is $110 to $120 million. Sales in 2018 were $64 million.

Best of luck with your investments!